

CURRENT REPORT 10/2022

July 1st, 2022

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") hereby announces that the following shareholders controlled at least 5% of the vote at the General Shareholders Meeting of the Company ("General Meeting") convened on June 30, 2022:

- 1. Paweł Przewięźlikowski, who held 3.900.544 shares of the Company and controlled 7.400.544 votes, which corresponds to 38,24% of the shares represented at the General Meeting, 51,93% of the votes represented at the General Meeting and 33,03% of the total number of votes;
- 2. Bogusław Sieczkowski, who held 825.348 shares of the Company and controlled 1.375.348 votes, which corresponds to 8,09% of the shares represented at the General Meeting, 9,65% of the votes represented at the General Meeting and 6,14% of the total number of votes;
- 3. Nationale-Nederlanden Otwarty Fundusz Emerytalny, which held 1.530.980 shares of the Company and controlled 1.530.980 votes, which corresponds to 15,01% of the shares represented at the General Meeting, 10,74% of the votes represented at the General Meeting and 6,83% of the total number of votes;
- 4. Augebit FIZ, which held 1.039.738 shares of the Company and controlled 1.039.738 votes, which corresponds to 10,19% of the shares represented at the General Meeting, 7,30% of the votes represented at the General Meeting and 4,64% of the total number of votes;
- 5. OFE PZU "Złota Jesień", which held 1.028.900 shares of the Company and controlled 1.028.900 votes, which corresponds to 10,09% of the shares represented at the General Meeting, 7,22% of the votes represented at the General Meeting and 4,59% of the total number of votes.
- 6. Aviva Otwarty Fundusz Emerytalny Santander, which held 1.532.000 shares of the Company and controlled 1.532.000 votes, which corresponds to 15,02% of the shares represented at the General Meeting, 10,75% of the votes represented at the General Meeting and 6,84% of the total number of votes.



According to the list of attendance at the General Meeting of the 10.200.030 shares of the Company (giving the right to 14.250.030 votes) were represented at the General Meeting.

The total number of shares in the Company is 18.355.474 and gives the right to 22.405.474 votes

Legal basis: Article 56.1.2 of the Act on Offerings

Representatives of the Issuer:

- Paweł Przewięźlikowski President of the Management Board
- Krzysztof Brzózka Vice President of the Management Board